For instance, about 70% of breast cancers are ER+ve malignancies, whereas HER2+ve tumors can be further classified into HER2+ve ER+ve and HER2+ve ER-ve which account for about 70% and 30%, respectively [9]. This evidence concerns the gene ERBB2 and breast carcinoma.